News

REGENXBIO Completes Enrollment for Gene Therapy Trials in AMD

REGENXBIO Completes Enrollment for Gene Therapy Trials in AMD

Enrollment Completed in Pivotal Trials for AMD Treatment

REGENXBIO Inc. (Nasdaq: RGNX) has successfully announced the completion of participant enrollment in its pivotal trials, ATMOSPHERE and ASCENT, which focus on the innovative gene therapy known as surabgene lomparvovec for the treatment of wet age-related macular degeneration (wet AMD).

Milestone Achieved for Gene Therapy

This achievement marks a groundbreaking moment in the field, as it represents the largest global gene therapy program ever conducted in relation to wet AMD, involving over 1,200 participants. These trials are designed to evaluate the effectiveness of surabgene lomparvovec delivered via subretinal injection, a method aimed at providing a long-lasting treatment for this debilitating eye condition.

Dr. Steve Pakola, Chief Medical Officer at REGENXBIO, shared his enthusiasm regarding the enrollment phase, stating, "Completing enrollment in this large, global pivotal program is an exciting milestone in our efforts to deliver sura-vec to patients as the potential first gene therapy for wet AMD." He expresses confidence in the necessity for new treatment options that can offer vision preservation, prevent disease progression, and alleviate the burden of ongoing intraocular injections characteristic of current treatments.

Understanding the Pivotal Trials

The ATMOSPHERE and ASCENT trials are meticulously designed as multi-center, randomized, active-controlled studies. The ATMOSPHERE trial, conducted in the United States, compares surabgene lomparvovec against ranibizumab. Simultaneously, the ASCENT trial spans across the U.S. and 13 other countries, against aflibercept. Together, these studies are crucial for supporting global regulatory submissions aimed at securing approval for this innovative therapy.

Details on Study Parameters

The primary objective of these trials is to assess non-inferiority based on the changes in Best Corrected Visual Acuity (BCVA) after 54 weeks and one year, respectively. Secondary endpoints will focus on the safety and tolerability of the treatment, changes in central retinal thickness, and the need for additional anti-VEGF injections during the study.

Promising Results from Earlier Studies

Previously conducted studies have demonstrated that surabgene lomparvovec is generally well tolerated and shows a durable treatment effect, with stable or improved vision observed in participants after up to four years. The positive outcomes from a Phase II pharmacodynamic study have further contributed to the growing anticipation for the topline data expected in the fourth quarter of 2026.

About Surabgene Lomparvovec

Surabgene lomparvovec, also identified as ABBV-RGX-314, is under evaluation as a potential one-time treatment for wet AMD, diabetic retinopathy, and other chronic retinal diseases. This innovative therapy employs the NAV AAV8 vector to encode an antibody fragment that targets vascular endothelial growth factor (VEGF), a significant contributor to the pathogenesis of wet AMD.

Exploring Wet AMD

Wet AMD leads to severe vision loss associated with abnormal blood vessel growth in the retina. Millions suffer from this condition, making it a pressing health concern in many developed countries. Current anti-VEGF therapies have transformed the landscape of treatment, showcasing their efficacy in slowing disease progression. However, they typically necessitate continuous, frequent intraocular injections, which can discourage patient adherence.

Company Overview

Founded in 2009, REGENXBIO is a biotechnology company dedicated to improving lives through gene therapy. The company is advancing a late-stage pipeline of one-time treatments aimed at addressing various diseases such as Duchenne muscular dystrophy and more. Their commitment to creating impactful treatments has positioned REGENXBIO at the forefront of gene therapy innovation.

Frequently Asked Questions

What is surabgene lomparvovec?

Surabgene lomparvovec is a gene therapy under development for wet AMD, designed to be delivered via a one-time subretinal injection to inhibit the growth of leaky blood vessels.

What are the ATMOSPHERE and ASCENT trials?

These are pivotal clinical trials aimed at evaluating the safety and efficacy of surabgene lomparvovec in treating wet AMD, involving over 1,200 participants globally.

When is topline data expected?

Topline data from these studies is expected to be released in the fourth quarter of 2026.

Why is there a need for new treatments for wet AMD?

Existing treatments require life-long frequent injections, which many patients find burdensome. New therapies such as surabgene lomparvovec aim to alleviate this burden by offering longer-lasting effects.

How does REGENXBIO contribute to the field of gene therapy?

REGENXBIO is pioneering innovative gene therapies using AAV vectors, advancing several promising treatments for various genetic and retinal conditions, significantly impacting patient care.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Babe Ruth Lots Lead Morphy's $2 Million Collectibles Auction

Updated Category News Views 44

Ruth still pulls money like few names ever will, and Morphy's November 10-12 auction made that plain without any circus tricks. Three lots tied to the Yankees legend produced $136,500 within a Toys, Sports & General Collectibles sale that topped $2 million. That is not some vague nostalgia story. Buyers put real dollars behind a 1932 U.S. Caramel card, a 1933 Goudey card,...

Continue Reading
Greenberg Traurig Adds Privacy Muscle in Denver Office

Updated Category News Views 21

Privacy work used to be the legal department's back-room plumbing; now it can jam an entire product launch. That is why Greenberg Traurig's decision to bring Amber Mednick in as of counsel in Denver deserves more attention than the usual law-firm hiring blurb. This is not a splashy deal, and nobody should pretend one lateral hire rewrites the competitive map. Still, it is...

Continue Reading
Digital Diabetes Care Has a Bigger Prize Than Devices

Updated Category News Views 107

A glucose sensor is becoming less a gadget than a running conversation between patient, clinician and software. That shift matters because diabetes management is leaving the occasional clinic visit and moving into daily life, where the useful product is not merely a reading but a pattern someone can act on. The sector deserves attention from investors, but it also...

Continue Reading
Avenir Nears 19.99% Grid Stake After Falcon West Resource

Updated Category News Views 11

Falcon West finally put enough geological meat on the bone to make Avenir reach for its wallet. Avenir Minerals expects to buy 29,388,127 Grid Metals common shares on or about November 30, 2026, taking its non-diluted position to 19.99%. That number is not accidental. It is the usual Canadian strategic-investor ceiling before the conversation starts getting considerably...

Continue Reading
Veterinary Biologics Growth Has a Valuable Catch Ahead

Updated Category News Views 94

Pet allergies and livestock disease are hardly glamorous, yet they are becoming a durable spending lane. The veterinary biologics market is projected to rise from $2.85 billion in 2026 to $3.69 billion by 2031, a 5.3% compound annual growth rate. That is not the kind of growth figure that makes anyone pound the table, and frankly it should not. It is the sort that can...

Continue Reading
TEN Holdings Raises $1.0 Million as Dilution Looms

Updated Category News Views 13

A Small Raise With a Loud Message Nothing says “we need room to breathe” quite like selling 1,492,500 new shares for $0.67 apiece. TEN Holdings closed a roughly $1.0 million gross equity offering on November 20, 2026, and investors in NASDAQ:XHLD ought to look at this for what it is: a modest cash infusion that comes with immediate dilution. The company gets capital;...

Continue Reading
RLX Revenue Soars, but European Margins Need Proof

Updated Category News Views 104

Revenue can wear a fancy suit while earnings arrive in work boots, and RLX Technology's third quarter is exactly that kind of report. The newly consolidated European distribution business pushed third-quarter revenue to RMB1.92 billion, up 69.7% year over year. That is a real jump, not pocket change. But the same acquisition also changed the mix, squeezed the blended...

Continue Reading
Rosenblatt Book Puts Vegas Casino Blind Spots on Display

Updated Category News Views 143

A locked casino floor is supposed to make secrets expensive. That is why the pitch behind ROSENBLATT lands with a little more weight than the usual Vegas chest-thumping: the coming memoir says Darryl Rosenblatt became a million-dollar gambler while using none of his own money, and that casino operators did not grasp the full shape of what had happened for years. Take a...

Continue Reading
Cash Flow Discipline Is Where Business Growth Gets Real

Updated Category News Views 55

A full order book can still leave a company gasping at payroll. That is the unglamorous point behind the Nov. 20, 2026, HelloNation piece featuring Kimberly Furrh of Furrh & Associates PC in Lawton, Oklahoma. Owners love to talk about sales because sales are visible, flattering and easy to celebrate. Cash is less theatrical. It is also the thing that keeps the lights on...

Continue Reading
CCTV-4 Revisits China's Enduring Academy Tradition

Updated Category News Views 86

Stone courtyards, old books and hard questions are getting prime time on CCTV-4, which is a more interesting programming bet than it may first appear. Enduring Chinese Academies, a ten-episode cultural exploration series from China Media Group's Global Chinese Programming Center, is built around a simple theme: “One academy, one spirit.” It begins airing November 22...

Continue Reading

Top 5 Most Recently Viewed Articles

Russel Metals Announces Conference Call Plans for Q3 2024

Updated Category News Views 80

Join the Discussion: Russel Metals Q3 2024 Conference Call Russel Metals Inc. presents an opportunity for investors and stakeholders to engage in dialogue regarding their third quarter performance in 2024. The conference call is scheduled to take place shortly after the release of the results, ensuring a comprehensive overview of the company's financial status. Conference...

Continue Reading
Investors Urged to Act in Fluor Corporation Securities Case

Updated Category News Views 358

Investors Urged to Act in Fluor Corporation Securities Case Kahn Swick & Foti, LLC, led by former Louisiana Attorney General Charles C. Foti, Jr., has issued an important reminder to investors regarding the Fluor Corporation (NYSE: FLR). If you experienced losses exceeding $100,000 by purchasing Fluor's securities within a specific timeframe, you have a limited window to...

Continue Reading
Exploring Consumer Product Risks: Insights from Legal Experts

Updated Category News Views 186

Investigation into Defective Consumer Products The Law Offices of Jason Turchin is currently investigating various claims related to defective consumer products that can potentially harm individuals. These products include commonly used items such as space heaters and HVAC systems, as well as kitchen equipment like coffee makers and pressure cookers. Each of these items...

Continue Reading
Empowering Older Adults: Take Action to Prevent Falls Today

Updated Category News Views 71

Empowering Older Adults to Prevent Falls Every year, millions of older adults fall, leading to serious injuries and long-term health complications. The upcoming Falls Prevention Awareness Week is designed to educate people on how to reduce these risks. This initiative focuses on making resources easily accessible and encourages community involvement, helping seniors live...

Continue Reading
Sealed Air Corporation Announces Significant Cash Dividend

Updated Category News Views 173

Sealed Air Corporation Announces Quarterly Cash Dividend Sealed Air Corporation (NYSE: SEE) has made a significant announcement regarding its commitment to shareholders. The company's Board of Directors has declared a quarterly cash dividend of $0.20 per common share. This decision reflects the company's strong financial performance and dedication to providing value to...

Continue Reading